Inhaler approved for cystic fibrosis patients - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Inhaler approved for cystic fibrosis patients

Posted: Updated:
MGN Online MGN Online
  • Most Popular StoriesMost Popular StoriesMore>>

  • UPDATE: Dirty Girl Mud Run scheduled in Charleston, WV now canceled

    UPDATE: Dirty Girl Mud Run scheduled in Charleston, WV now canceled

    Tuesday, July 22 2014 11:38 PM EDT2014-07-23 03:38:13 GMT
    UPDATE: 13 NEWS has learned the Dirty Girl Mud Run has been officially canceled for this weekend in Charleston. 
    UPDATE: 13 NEWS has learned the Dirty Girl Mud Run has been officially canceled for this weekend in Charleston. 
  • Gas station robbed in Huntington, WV; police searching for suspects

    Gas station robbed in Huntington, WV; police searching for suspects

    Tuesday, July 22 2014 4:22 PM EDT2014-07-22 20:22:54 GMT
    Troopers with the West Virginia State Police are investigating a robbery at the Rich Oil gas station on Waverly Road in Huntington.
    Troopers with the West Virginia State Police are investigating a robbery at the Rich Oil gas station on Waverly Road in Huntington.
  • UPDATE: Man shot during fight on Charleston's east end

    UPDATE: Man shot during fight on Charleston's east end

    Tuesday, July 22 2014 9:10 PM EDT2014-07-23 01:10:50 GMT
    A man was shot in the hand during a robbery on Charleston's east end on July 22 at about 10:30 a.m.
    A man was shot in the hand during a robbery on Charleston's east end on July 22 at about 10:30 a.m.

MONDAY, March 25 (HealthDay News) -- The TOBI Podhaler (tobramycin inhalation powder) has been approved by the U.S. Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bacterium that can damage the lungs.

Cystic fibrosis, affecting about 30,000 people in the United States, causes production of thick, sticky mucus that builds up in the lungs. This can lead to chronic bacterial infections, the FDA said in a news release.

The TOBI Podhaler, used twice daily, was evaluated in clinical trials involving 95 adults and children six years and older with cystic fibrosis. The most common side effects included cough, coughing up blood, shortness of breath, fever, mouth and throat pain, changes in voice and headache.

The antibiotic inhaler is marketed by Novartis, based in East Hanover, N.J.